AwesomeCapital
Monday, September 30, 2019
Genentech to present positive Tecentriq data
›
Genentech ( OTCQX:RHHBY ) is presenting positive results from the Phase III IMvigor130 study evaluating Tecentriq (atezolizumab) today at t...
Aquestive completes early-stage AQST-108 trial
›
Aquestive Therapeutics (NASDAQ: AQST ) has completed its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108....
Moderna announces open IND for Propionic Acidemia program
›
The FDA has completed the review of Moderna’s (NASDAQ: MRNA ) IND application for mRNA-3927, its investigational mRNA therapeutic for pro...
Endo International rises 2.2% after litigation matters resolved
›
Endo International (NASDAQ: ENDP ) gains 2.2% in premarket trading after the culmination of two litigation matters regarding the compou...
Mallinckrodt +13% after settling Ohio opioid cases
›
Mallinckrodt (NYSE: MNK ) races higher in early trading after settling a legal case with two counties in Ohio involving opioid usage. T...
FDA OKs Turning Point’s IND for TPX-0046
›
The FDA clears Turning Point Therapeutics’ (NASDAQ: TPTX ) IND for TPX-0046, a novel therapy targeting solid tumors with abnormal RET gen...
Acasti Pharma updates on Trilogy 1 and 2 trials
›
Acasti Pharma (NASDAQ: ACST ) reports additional milestones reached and provides a business update on its clinical trials. ACST’s TRILO...
‹
›
Home
View web version